Danaher Corporation

DHR Healthcare Diagnostics & Research

Danaher Corporation’s revenue for fiscal 2025 (year ended December 2025) was $24.6 billion, up 2.90% from fiscal 2024.

Revenue
+8.28%
EPS
+36.7%
Free cash flow
+19.1%
Total debt
+44.9%

Quarter to September 2026, against a year earlier

229.99 3.65 +1.61%
Market cap
$159.2B
P/E
37.0×
Fwd P/E
36.9×
Dividend yield
0.67%
F-score
6/9
Altman Z
4.52
Beneish M
−2.57
Dividend safety
69/100

Danaher Corporation 10-Q filed Jul 22, 2025

Fiscal Q2 2025 · Period ended Jun 27, 2025 · Filed · accepted 6:39 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Apr 22, 2025: 29 added · 5 removed · 51 modified; 19 with only figures updated

  1. Modified · •Critical Accounting Estimates

    You should read this discussion along with the Company’s MD&A and audited financial statements and Notes thereto as of and for the year ended December 31, 2024, included in the Company’s 2024 Annual Report and the Company’s Consolidated Condensed Financial Statements and related Notes as of and for the three-month period three and six-month periods ended March 28June 27, 2025 included in this Quarterly Report on Form 10-Q (“Report”).